Aldeyra Therapeutics (NASDAQ:ALDX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03), Fidelity Earnings reports.
Aldeyra Therapeutics traded up $0.30, reaching $7.75, during trading on Friday, MarketBeat.com reports. The stock had a trading volume of 85,382 shares, compared to its average volume of 86,283. Aldeyra Therapeutics has a 1-year low of $3.90 and a 1-year high of $11.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.09 and a quick ratio of 11.09. The firm has a market capitalization of $149.02 million, a P/E ratio of -5.54 and a beta of 0.45.
ALDX has been the subject of a number of research reports. ValuEngine raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Cantor Fitzgerald set a $23.00 price target on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 15th. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 21st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 price target on shares of Aldeyra Therapeutics in a research report on Friday. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Aldeyra Therapeutics currently has a consensus rating of “Buy” and an average price target of $16.90.
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
See Also: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.